There are few medications with a history as unusual as methylene blue. Originally synthesized in the late nineteenth century as a textile dye, it quickly found its way into medicine. Physicians discovered that this vivid blue compound could selectively stain tissues under a microscope, helping scientists better understand the human body. Not long after, researchers realized it possessed remarkable biological properties of its own.

More than a century later, methylene blue remains an important hospital medication. It is the FDA-approved treatment for methemoglobinemia, a rare but potentially life-threatening condition that prevents red blood cells from carrying oxygen effectively. It is also used in operating rooms to identify lymph nodes and blood vessels, serves as an antidote for certain poisonings, and has become an important therapy in several critical care settings.

In recent years, however, methylene blue has found itself at the center of an entirely different conversation. Longevity physicians, neuroscientists, and biohackers have become increasingly interested in its potential effects on mitochondrial function, cognitive performance, cellular energy production, and healthy aging. Social media has amplified these discussions, often portraying methylene blue as a breakthrough nootropic capable of enhancing memory, increasing energy, or even slowing aging itself.

The scientific reality is considerably more nuanced. Some of the proposed mechanisms are biologically plausible. Laboratory research suggests methylene blue may improve mitochondrial efficiency, reduce oxidative stress, and influence how neurons generate energy. Animal studies have produced intriguing results, and early human research continues to explore potential applications in cognitive disorders and neurodegenerative disease.

At the same time, many of the claims circulating online remain unproven. Well-designed clinical trials are still limited, findings have been mixed, and methylene blue is far from a universal therapy. Like any prescription medication, it carries meaningful risks, including potentially dangerous interactions with commonly prescribed antidepressants and serious complications in certain medical conditions.

Understanding where the evidence is strong, and where it remains preliminary, is essential before considering methylene blue therapy.

Why Researchers Are Paying Attention

Much of the excitement surrounding methylene blue stems from one simple idea: healthy cells require healthy mitochondria.

Mitochondria are often described as the power plants of our cells because they convert nutrients into adenosine triphosphate (ATP), the molecule that provides energy for nearly every biological process. Every heartbeat, every muscle contraction, every thought, and every immune response depends on this continuous production of cellular energy.

As we age, or develop chronic disease, mitochondrial function can become less efficient. Researchers have linked impaired mitochondrial function to a wide range of conditions, including neurodegenerative disease, metabolic disorders, cardiovascular disease, chronic fatigue, and age-related cognitive decline. While mitochondria are not the sole cause of these conditions, their health appears to influence how well cells respond to stress, repair damage, and maintain normal function over time.

This is where methylene blue becomes scientifically interesting. Unlike many compounds promoted for longevity, methylene blue has a well-understood pharmacologic profile developed over decades of clinical use. Researchers already know how it behaves in the body, how it is metabolized, and which biological pathways it affects.

Rather than acting as a hormone or stimulant, methylene blue functions primarily as a redox agent, a molecule capable of accepting and donating electrons during chemical reactions. That seemingly simple characteristic has surprisingly broad implications throughout human physiology.

Precision Medicine Means Looking Beyond a Single Molecule

At Fountain Health, we believe one of the greatest misconceptions in longevity medicine is the search for a single intervention capable of solving complex biological problems.

Health does not decline because one molecule disappears. It changes because multiple interconnected systems gradually shift over time.

Sleep quality influences hormone production. Hormones affect metabolism. Metabolism shapes inflammation. Inflammation impacts mitochondrial function. Mitochondria influence cognitive performance, energy, recovery, and resilience.

Every biological system communicates with every other. This interconnected view is the foundation of precision medicine. Rather than asking whether methylene blue is "good" or "bad," we ask a different question:

Under what circumstances might it provide meaningful benefit, and for which patients?

Sometimes the answer may be yes. Often, the answer may be no. The decision depends on the individual biology, not the headline.

That philosophy explains why physician oversight remains essential. A therapy that is appropriate for one patient may be ineffective or even unsafe for another depending on medical history, current medications, underlying conditions, and treatment goals. (Additional read: Precision Mental Health: A New Standard for Mental Health Care)

Methylene blue is no exception. Its growing popularity should not obscure an important fact: this is a prescription medication with well-established medical uses, emerging areas of research, and clinically significant safety considerations.

You are likely to be reading this article, because you heard of methylene blue. The goal here is not to suggest what's trending, but rather to make a point that only when one's biology is understood, the right intervention at the right time for the right patient can be selected.

The Promise and the Limits of Mitochondrial Medicine

One of the defining characteristics of modern medicine is that we are beginning to look upstream. For decades, physicians have largely treated the consequences of disease. Elevated blood pressure is lowered. Blood sugar is controlled. Depression is managed. Heart failure is stabilized. These treatments are often lifesaving, but they typically intervene after biological dysfunction has already become established.

Longevity medicine asks a different question. Can we identify changes in cellular function before they become disease? That question has brought mitochondria into the spotlight.

Often called the "powerhouses" of the cell, mitochondria do far more than generate energy. They help regulate inflammation, oxidative stress, calcium signaling, programmed cell death, and the production of many of the molecules required for normal cellular function. Every organ depends on healthy mitochondria, but few rely on them as heavily as the brain, heart, muscles, and immune system.

As we age, mitochondrial performance appears to decline. The reasons are complex and still being investigated, but researchers have identified several recurring themes: accumulated oxidative damage, chronic inflammation, impaired metabolic flexibility, reduced mitochondrial turnover, and changes in the efficiency of the electron transport chain.

Collectively, these changes may contribute to the gradual loss of resilience that many people associate with aging.

Recovery takes longer and exercise feels more difficult. Mental clarity becomes less consistent and sleep becomes less restorative. The body still functions, but often with less reserve than it once had. Scientists are increasingly asking whether improving mitochondrial function could help preserve health rather than simply treating disease after it appears.

This is where methylene blue enters the conversation. It has not been proven to slow aging, neither it is a miracle compound. But its pharmacology suggests it may influence one of the body's most fundamental biological processes: cellular energy production. That distinction is critical.

A molecule can affect an important biological pathway without necessarily producing meaningful clinical outcomes. Medicine is filled with compounds that looked extraordinary in a laboratory but failed to improve patients' lives when tested in rigorous clinical trials.

The goal of research is to determine whether methylene blue belongs in the small group of interventions that successfully make that transition.

Over the past decade, advances in mitochondrial biology have transformed how scientists think about cellular health. Researchers such as Martin Picard, PhD, whose work at Columbia University has helped redefine mitochondria as central regulators of cellular communication, stress adaptation, and aging, argue that these organelles are far more than the cell's "power plants." They function as dynamic signaling networks that influence virtually every aspect of human physiology. Within that broader context, compounds capable of influencing mitochondrial function, including methylene blue, have attracted growing scientific interest.

Methylene Blue and Brain Health

Few organs demand more energy than the human brain. Although, the brain represents only about two percent of total body weight, it consumes roughly one-fifth of the body's available oxygen and energy. Every memory, decision, emotion, and movement depends on a constant supply of ATP generated inside neurons.

When mitochondrial function declines, the brain often notices first. This relationship has led scientists to investigate whether therapies that support mitochondrial function could also support cognitive performance.

Methylene blue has become one of the more intriguing candidates. In laboratory studies, researchers have observed that methylene blue may reduce oxidative stress, improve mitochondrial respiration, and enhance neuronal survival under certain experimental conditions. Animal studies have demonstrated improvements in learning and memory, while several early human imaging studies suggest that low doses may influence activity in brain regions involved in memory processing.

These findings have fueled considerable excitement. They have also fueled considerable exaggeration. Scroll through social media and you'll quickly encounter claims that methylene blue enhances intelligence, dramatically improves memory, reverses dementia, or functions as a universal nootropic. Those statements go far beyond the available evidence. The reality is far more measured.

Human studies remain relatively small, vary considerably in methodology, and often examine short-term physiological changes rather than long-term clinical outcomes. Some investigations have reported encouraging findings, while others have shown minimal benefit or conflicting results. One recent study even found decreased cerebral blood flow following methylene blue administration, illustrating that the compound's effects on healthy individuals remain incompletely understood.

This uncertainty should not discourage research. It should encourage careful interpretation. Medicine advances by asking difficult questions, not by assuming every promising laboratory finding has already become clinical fact.

Can Methylene Blue Slow Aging?

Perhaps no claim surrounding methylene blue has attracted more attention than its proposed role in longevity. The idea is understandable. If aging is associated with declining mitochondrial efficiency, and methylene blue appears capable of influencing mitochondrial function, perhaps it could slow aspects of biological aging. However, the conclusion is not yet supported.

At present, there is no convincing clinical evidence demonstrating that methylene blue extends human lifespan or reliably slows biological aging. Researchers continue to investigate whether it may influence biomarkers associated with healthy aging, but these studies remain early.

This distinction matters because longevity medicine has become increasingly vulnerable to oversimplification. Every few months, another compound is introduced as the molecule that will "reverse aging." Before that, it was NMN, then resveratrol, spermidine, rapamycin. Now methylene blue has joined the conversation.

History reminds us that biology rarely rewards certainty. Healthy aging is unlikely to depend on a single molecule. Instead, it reflects the cumulative interaction of genetics, nutrition, physical activity, sleep, metabolic health, inflammation, hormonal balance, environmental exposures, and countless other variables that influence human physiology throughout life.

At Fountain Health, that systems perspective guides every clinical decision. When evaluating any emerging therapy, including methylene blue, the question is never simply: "Does it work?" The more useful question is: "Who, under what circumstances, at what dose, and as part of what overall treatment strategy will benefit from it?" That shift in thinking represents the difference between precision medicine and trend-driven medicine.

Understanding Dosing

One of the most concerning aspects of methylene blue's popularity is how casually dosing is often discussed online. Search social media or longevity forums and you'll find recommendations ranging from a few milligrams per day to dramatically higher amounts, frequently with little explanation of why those doses were chosen or whether they have been studied. This is not how medications should be approached.

For its FDA-approved indication, methemoglobinemia, methylene blue is administered intravenously at approximately 1 mg per kilogram of body weight, typically infused over five to thirty minutes. If symptoms persist, a second dose may be administered after clinical reassessment. In vasoplegic shock, dosing strategies differ and remain under physician supervision in intensive care settings.

Outside these established indications, dosing becomes far less certain. Compounded oral preparations marketed for cognitive support or longevity frequently recommend daily doses between 4 and 30 milligrams, but these regimens are not supported by the same level of evidence as approved medical uses. They are based largely on theoretical mechanisms, observational experience, and limited clinical investigation rather than large randomized trials.

More is not necessarily better. In fact, methylene blue demonstrates what pharmacologists describe as a biphasic dose-response. At relatively low concentrations, certain biological effects may appear favorable. At substantially higher doses, however, the compound can become counterproductive and increase the risk of toxicity.

This phenomenon underscores a broader principle of precision medicine. Effective therapy is rarely about maximizing dose. It is about identifying the smallest dose capable of producing the desired biological effect while minimizing unnecessary risk. That determination belongs within the physician-patient relationship, and outside of an internet forum or chat.

What Is Methylene Blue? How It Works Inside the Body

Methylene blue is one of the more unusual compounds in modern medicine. It began as a synthetic dye. It was later used by scientists to stain cells and tissues under the microscope. Over time, physicians discovered that it did more than color what they wanted to see. Inside the body, methylene blue could participate in some of the most basic chemical reactions that keep cells alive.

That is why it remains medically relevant more than a century after it was first synthesized.

Today, methylene blue is best known as an FDA-approved intravenous treatment for methemoglobinemia, a rare but serious condition in which hemoglobin can no longer carry oxygen normally. It is also used in certain hospital, surgical, toxicology, and cancer-supportive care settings. Its newer reputation in longevity and cognitive health comes from a different question: could the same chemistry that helps restore oxygen delivery also support how cells produce energy?

To understand that possibility, it helps to understand what methylene blue does at the molecular level. Methylene blue is a redox agent. That means it can accept and donate electrons during chemical reactions. Electron transfer may sound abstract, but it is central to life. Cells move electrons constantly to produce energy, repair damage, control oxidative stress, and maintain normal function.

In methemoglobinemia, this electron-shuttling ability has a clear and established purpose.

Normally, hemoglobin inside red blood cells carries oxygen from the lungs to tissues throughout the body. In methemoglobinemia, the iron inside hemoglobin becomes oxidized. Once that happens, hemoglobin is converted into methemoglobin, which cannot bind and deliver oxygen effectively.

A patient may have oxygen in the bloodstream, but the body cannot use it properly. This can lead to blue or gray skin discoloration, shortness of breath, dizziness, confusion, rapid heart rate, and in severe cases, seizures, organ injury, or death. Methylene blue helps reverse this process. Given intravenously under medical supervision, it helps convert methemoglobin back into functional hemoglobin, allowing the blood to carry oxygen again. In appropriate patients, improvement can occur quickly, sometimes within minutes to an hour.

That same redox chemistry is also why researchers are studying methylene blue in mitochondria. Mitochondria are the energy-producing structures inside cells. They generate ATP, the molecule that powers nearly every biological process in the body. To do this, mitochondria rely on a system called the electron transport chain, where electrons move through a sequence of protein complexes to help produce usable cellular energy.

When this system becomes less efficient, cells may produce less energy and more oxidative stress. This pattern has been studied in aging, neurodegenerative disease, fatigue, metabolic dysfunction, and other conditions where cellular energy may be impaired.

Laboratory research suggests methylene blue may act as an alternative electron carrier inside mitochondria. In theory, it may help electrons move more efficiently through parts of the energy-producing system, support ATP production, and reduce oxidative stress under certain conditions. This is one reason researchers have become interested in its potential role in brain health, mitochondrial function, and healthy aging.

But this is where the distinction between mechanism and medicine becomes important. A molecule can do something interesting in a cell model without producing meaningful benefits in real patients. Methylene blue has shown promise in laboratory and animal studies, and some early human research has explored its effects on memory, mood, brain metabolism, and neurodegenerative disease. But the evidence is not yet strong enough to support many of the claims now circulating online.

Some findings are encouraging. Others are mixed. At least one recent study found decreased cerebral blood flow after methylene blue administration, which reminds us that its effects in healthy individuals are still not fully understood. So the most accurate answer is also the most clinically responsible one: Methylene blue is a proven medication in specific medical settings. It is a scientifically interesting compound in mitochondrial and cognitive research. It is not a proven anti-aging cure, universal nootropic, or supplement that belongs in everyone’s routine.

At Fountain Health, that distinction matters. The question is not whether methylene blue is “good” or “bad.” The question is whether it is appropriate for a specific patient, with a specific biology, a specific medical history, and a clear clinical reason for considering it.

The Most Important Conversation: Is Methylene Blue Safe?

For a molecule with more than a century of medical history, methylene blue has accumulated an unusual amount of mythology. Some online discussions portray it as a virtually risk-free longevity supplement. Others describe it as a dangerous chemical that should be avoided entirely. Neither view reflects the reality physicians see in clinical practice.

When used for approved medical indications under appropriate supervision, methylene blue has a well-established safety profile. It has been administered in hospitals for decades, and clinicians understand its pharmacology, expected effects, dosing principles, and potential complications.

Problems arise when that context is removed. Increasingly, methylene blue is being marketed directly to consumers as a nootropic, anti-aging supplement, or "mitochondrial optimizer." In many cases, recommendations circulate without any discussion of prescription medications, underlying medical conditions, laboratory testing, or appropriate monitoring.

That is precisely where risk begins. Like every prescription medication, methylene blue has contraindications, clinically important drug interactions, and situations in which it simply should not be used. Understanding those risks is every bit as important as understanding its potential benefits.

The Risk Most Physicians Worry About: Serotonin Syndrome

If physicians have one major concern about inappropriate methylene blue use, it is serotonin syndrome. This complication is uncommon, but when it occurs, it can become life-threatening.

The reason lies in the way methylene blue interacts with the nervous system. In addition to its redox properties, methylene blue also functions as a monoamine oxidase inhibitor (MAOI). Monoamine oxidase is an enzyme responsible for breaking down neurotransmitters such as serotonin. When that enzyme is inhibited, serotonin levels may rise.

On its own, this effect is usually manageable.The danger appears when methylene blue is combined with other medications that also increase serotonin. These include many of the most commonly prescribed psychiatric medications, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), MAOIs, certain tricyclic antidepressants, some migraine medications, several opioids, dextromethorphan-containing cough medicines, and a variety of other prescription drugs.

When serotonin accumulates excessively, the nervous system can become dangerously overstimulated. Symptoms may begin with restlessness, tremor, sweating, dilated pupils, or agitation. As the condition progresses, patients can develop high fever, severe muscle rigidity, rapid heart rate, elevated blood pressure, confusion, seizures, and organ dysfunction.

Serotonin syndrome is a medical emergency. Fortunately, it is also largely preventable. Before methylene blue is administered, physicians routinely review every prescription medication, over-the-counter product, and dietary supplement a patient is taking. In some situations, treatment may be delayed, alternative therapies may be selected, or medications may need to be temporarily discontinued under careful supervision.

This is one reason self-prescribing methylene blue is strongly discouraged. No online dosing calculator can evaluate medication interactions with the same level of safety as a thorough clinical review.

Who Should Not Receive Methylene Blue?

Like many medications, methylene blue is highly appropriate for some patients and clearly inappropriate for others. One of the most important contraindications is glucose-6-phosphate dehydrogenase (G6PD) deficiency, an inherited enzyme disorder that affects millions of people worldwide.

Patients with G6PD deficiency lack one of the protective mechanisms red blood cells use to defend themselves against oxidative stress. Ironically, the medication used to restore oxygen transport in most patients can cause red blood cells to rupture in individuals with this condition, leading to hemolytic anemia. For that reason, methylene blue is generally avoided in patients known to have G6PD deficiency.

Pregnancy is another situation that requires particular caution. Although methylene blue has important medical uses, it has also been associated with fetal harm when administered during pregnancy. Decisions regarding its use must balance potential maternal benefit against fetal risk and should occur only under specialist medical supervision.

Additional caution is warranted in patients with significant kidney or liver disease, where drug metabolism and elimination may be altered, as well as in individuals with known hypersensitivity to methylene blue or related compounds.

These precautions are not unique to methylene blue. They reflect a broader principle of good medicine: every treatment recommendation begins with understanding the patient—not the medication.

Understanding Side Effects

Some side effects of methylene blue are expected. Others require immediate medical attention. One of the most surprising, but completely harmless effects is the dramatic change in urine color. Because methylene blue is excreted through the kidneys, urine commonly turns a vivid blue or blue-green within hours after treatment. Stool may also develop a greenish tint for a short period. For patients who have never experienced this before, the color change can be alarming. In reality, it is simply evidence that the medication is leaving the body and usually resolves on its own.

Other relatively common side effects include mild nausea, vomiting, headache, temporary skin discoloration, and discomfort at the intravenous infusion site. Patients using methylene blue mouth rinses for oral mucositis may notice temporary burning or altered taste sensations.

Serious adverse reactions are considerably less common but deserve attention. These include severe allergic reactions, profound hypertension, cardiac rhythm disturbances, confusion, seizures, significant hemolysis, and serotonin syndrome. Although uncommon, they reinforce why methylene blue should be administered within an appropriate medical framework rather than treated as an ordinary dietary supplement.

Why Medical Supervision Matters

One of the most persistent misconceptions in longevity medicine is that physician oversight exists primarily to prescribe medications. In reality, prescribing is often the least important part of the process. The greater responsibility is deciding whether a medication should be prescribed at all. That decision cannot be made by looking at a single symptom. It requires understanding the patient's medications, laboratory values, medical history, cardiovascular risk, neurological history, goals, expectations, and the balance between potential benefit and potential harm. This is particularly true for therapies like methylene blue, where enthusiasm generated by laboratory research has begun to outpace clinical evidence.

At Fountain Health, no intervention exists in isolation. Whether considering methylene blue, ketamine therapy, peptide protocols, metabolic optimization, or hormone replacement, the process begins with the same question: What is driving this patient's biology?

Only after that question is answered does it make sense to discuss treatment options. That approach is slower than following trends. It is also how precision medicine is intended to work.

What to Expect During Methylene Blue Therapy

If you've been reading about methylene blue online, you might imagine it as another wellness infusion offered alongside vitamins or NAD+. In situ, the experience depends entirely on why the medication is being used.

For its FDA-approved indication—methemoglobinemia—methylene blue is administered in a hospital or emergency department. Patients receive the medication intravenously, usually over five to thirty minutes, while clinicians closely monitor oxygen levels, heart rate, blood pressure, and overall response. Because the medication acts directly on dysfunctional hemoglobin, improvement often begins quickly. As oxygen delivery is restored, symptoms such as shortness of breath, fatigue, dizziness, and cyanosis frequently begin to resolve within minutes to an hour.

Hospital physicians may also administer methylene blue during complex surgical procedures, in intensive care settings, or as part of cancer supportive care. In each of these situations, dosing, monitoring, and follow-up are tailored to the clinical problem being treated.

Outside of these established medical settings, methylene blue has become increasingly available through compounding pharmacies and longevity clinics. This is where patients should exercise particular caution.

Unlike emergency medicine, there is currently no universally accepted protocol for using methylene blue to support cognitive health, mitochondrial function, or healthy aging. Dosing strategies vary considerably, long-term safety data remain limited, and many proposed applications continue to be investigated rather than established.

For patients considering these therapies, the first appointment should not revolve around receiving methylene blue. It should revolve around determining whether methylene blue belongs in the conversation at all. A thoughtful evaluation typically includes a review of your medical history, current medications, prior diagnoses, laboratory data, cardiovascular health, neurological history, and treatment goals. Particular attention should be paid to antidepressants and other serotonergic medications, as these may make methylene blue inappropriate regardless of its theoretical benefits.

If treatment is considered appropriate, your clinician should explain exactly why it is being recommended, what evidence supports that decision, what remains uncertain, and how progress will be monitored over time. That conversation is far more valuable than simply receiving a prescription.

Setting Realistic Expectations

One reason methylene blue has generated so much enthusiasm is that it sits at the intersection of several exciting areas of medicine: mitochondrial biology, neuroscience, longevity research, and precision medicine.

Those fields are advancing rapidly. So is the public appetite for interventions that promise more energy, sharper thinking, and healthier aging. The temptation is to believe that one compound might address many of these goals simultaneously. Medicine rarely works that way.

The biology of aging is extraordinarily complex. Sleep quality, nutrition, exercise, metabolic health, chronic inflammation, hormonal balance, genetics, environmental exposures, and psychological well-being all interact continuously throughout life. No medication, regardless of how promising, can replace those foundations. That doesn't diminish methylene blue's scientific interest. Quite the opposite.

Its ability to participate in fundamental cellular processes makes it one of the more intriguing compounds currently under investigation. Researchers continue to explore its potential role in neurodegenerative disease, traumatic brain injury, mitochondrial disorders, critical care medicine, and other conditions where cellular energy production may be impaired.

Some of those investigations may ultimately change clinical practice. Others may not. Every accepted therapy was once an unanswered question. The responsibility of medicine is to distinguish between hypotheses that are biologically plausible, therapies that appear promising, and treatments that have been proven to improve patient outcomes. Those are not the same thing.

The Fountain Perspective

At Fountain Health, we are optimistic about innovation. We are equally committed to evidence. Throughout history, medicine has repeatedly advanced because physicians remained open to new ideas while demanding rigorous proof before embracing them. Methylene blue represents exactly this kind of opportunity. It is an established hospital medication with a fascinating pharmacology, legitimate scientific momentum, and emerging applications that deserve careful investigation. It is also a reminder that no molecule exists in isolation.

A patient's biology is shaped by thousands of interconnected variables: genetics, metabolism, inflammation, nutrition, sleep, hormones, medications, environmental exposures, and the extraordinary capacity of the body to adapt over time. (Additional read: Mental Health Is Biological)

The future of longevity medicine will not be built on finding one remarkable compound.

It will be built on understanding how those biological systems interact within each individual, and selecting interventions that are appropriate for that person's unique physiology.

Sometimes methylene blue may become part of that conversation. Sometimes it will not. Our goal is to pursue what is most likely to help, not the newest molecule. That is the difference between following trends and practicing precision medicine.

References

Harvard Health Publishing. What to Know About Methylene Blue. Published April 24, 2025. Available at: https://www.health.harvard.edu/medications-and-treatments/what-to-know-about-methylene-blue

Picard M, Shirihai OS. Mitochondrial Signal Transduction. Cell Metabolism. 2022 https://pubmed.ncbi.nlm.nih.gov/36323233/

StatPearls Publishing. Clifton J, Leikin JB. Methylene Blue. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Updated January 2026. Available at: https://www.ncbi.nlm.nih.gov/books/NBK557593/

National Library of Medicine (NCBI Bookshelf). Methylene Blue. Available through StatPearls clinical review. https://www.ncbi.nlm.nih.gov/books/NBK557593/

WebMD. Methylene Blue: Uses, Benefits, Side Effects & How It Works. Updated April 2025. https://www.webmd.com/a-to-z-guides/methylene-blue

Mayo Clinic. Methylene Blue (Intravenous Route): Description, Precautions and Side Effects. https://www.mayoclinic.org/drugs-supplements/methylene-blue-intravenous-route/description/drg-20064695

Cleveland Clinic. Methylene Blue Injection (ProvayBlue): Uses & Side Effects. https://my.clevelandclinic.org/health/drugs/20881-methylene-blue-injection

MD Anderson Cancer Center. Methylene Blue: Should You Take It? https://www.mdanderson.org/cancerwise/methylene-blue-should-you-take-it.h00-159853767.html

Baptist Health South Florida. What to Know About Methylene Blue: Benefits, Risks, and Expert Guidance. https://baptisthealth.net/baptist-health-news/methylene-blue-benefits-risks-and-expert-guidance

FDA Prescribing Information. ProvayBlue® (Methylene Blue Injection). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/

Ginimuge PR, Jyothi SD. Methylene Blue: Revisited. Journal of Anaesthesiology Clinical Pharmacology. 2010;26(4):517-520. https://pmc.ncbi.nlm.nih.gov/articles/PMC3087269/

Atamna H, Nguyen A, Schultz C, et al. Methylene Blue Delays Cellular Senescence and Enhances Key Mitochondrial Biochemical Pathways. The FASEB Journal. 2015. https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.14-259598

Rojas JC, Bruchey AK, Gonzalez-Lima F. Low-Dose Methylene Blue Improves Memory Retention in Healthy Adults. Psychopharmacology. 2012. https://link.springer.com/article/10.1007/s00213-012-2771-8

Rodriguez P, et al. Effects of Low-Dose Methylene Blue on Cerebral Blood Flow and Brain Function. (Referenced in Harvard Health review discussing conflicting findings.)*

Medical Review:

Medically reviewed for clinical accuracy by Doreen Zarfati, MD, Chief Medical Officer, Fountain Health NYC.
Our editorial team reviews current peer-reviewed research and guidance from leading academic medical institutions to ensure our content is accurate, balanced, and evidence-based. Because medical research continues to evolve, this article is intended for educational purposes and should not replace individualized medical advice.

Methylene Blue: The Science Behind One of Medicine's Most Unexpected Molecules